These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22529171)

  • 1. Surge in Down syndrome prenatal testing anticipated.
    Collier R
    CMAJ; 2012 Jun; 184(9):E449-50. PubMed ID: 22529171
    [No Abstract]   [Full Text] [Related]  

  • 2. The cost of choice: a price too high in the triple screen for Down syndrome.
    Elkins TE; Brown D
    Clin Obstet Gynecol; 1993 Sep; 36(3):532-40. PubMed ID: 7691458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid aneuploidy test for positive Down screening: who is willing to pay for it?
    Lo TK; Leung WC; Lau WL; Lam H; Lai FK; Ng LS; Wong WC; Chan A; Chin RK
    J Matern Fetal Neonatal Med; 2010 Jul; 23(7):747-9. PubMed ID: 19701862
    [No Abstract]   [Full Text] [Related]  

  • 4. Maternal serum triple analyte screening in pregnancy.
    Cate S
    Am Fam Physician; 2000 Aug; 62(4):738, 740. PubMed ID: 10969855
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of prenatal screening and diagnostic strategies for Down syndrome: A microsimulation modeling analysis.
    Zhang W; Mohammadi T; Sou J; Anis AH
    PLoS One; 2019; 14(12):e0225281. PubMed ID: 31800591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility and cost of non-invasive prenatal testing.
    Cuckle H; Benn P; Pergament E
    J Matern Fetal Neonatal Med; 2014 Feb; 27(3):320-1. PubMed ID: 23875873
    [No Abstract]   [Full Text] [Related]  

  • 7. The contingent use of cell-free fetal DNA for prenatal screening of trisomies 21, 18, 13 in pregnant women within a national health service: A budget impact analysis.
    Prefumo F; Paolini D; Speranza G; Palmisano M; Dionisi M; Camurri L
    PLoS One; 2019; 14(6):e0218166. PubMed ID: 31188879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-benefit analysis of prenatal diagnosis for Down syndrome using the British or the American approach.
    Walker M; Pandya P
    Obstet Gynecol; 2000 Sep; 96(3):481. PubMed ID: 11001699
    [No Abstract]   [Full Text] [Related]  

  • 9. First trimester screening: economic implications.
    Macones GA; Odibo A
    Semin Perinatol; 2005 Aug; 29(4):263-6. PubMed ID: 16104679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should all pregnant patients be offered prenatal diagnosis regardless of age?
    St Amant M; Elkins TE; Brown D; Pastorek JG
    Obstet Gynecol; 1993 Aug; 82(2):315-6. PubMed ID: 8336885
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness and accuracy of prenatal Down syndrome screening strategies: should the combined test continue to be widely used?
    Gekas J; Durand A; Bujold E; Vallée M; Forest JC; Rousseau F; Reinharz D
    Am J Obstet Gynecol; 2011 Feb; 204(2):175.e1-8. PubMed ID: 21074138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the benefits of antenatal screening: an alternative approach.
    Shackley P; Cairns J
    Health Policy; 1996 May; 36(2):103-15. PubMed ID: 10158764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost utility of prenatal diagnosis.
    Bradbury I; Wright D; Slattery J; Ritchie K
    Lancet; 2004 Apr; 363(9415):1164-5; author reply 1165. PubMed ID: 15064048
    [No Abstract]   [Full Text] [Related]  

  • 14. Pre-natal screening for Down's syndrome.
    Phillips A; Wakeman A
    J Public Health Med; 1994 Mar; 16(1):114-5; author reply 116-7. PubMed ID: 8080557
    [No Abstract]   [Full Text] [Related]  

  • 15. Author response to letter from Song et al.
    Song K; Musci T; Caughey AB
    J Matern Fetal Neonatal Med; 2014 Jun; 27(9):972. PubMed ID: 24007257
    [No Abstract]   [Full Text] [Related]  

  • 16. An economic appraisal of screening for Down's syndrome in pregnancy using maternal age and serum alpha fetoprotein concentration.
    Gill M; Murday V; Slack J
    Soc Sci Med; 1987; 24(9):725-31. PubMed ID: 2440113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost and efficacy comparison of prenatal recall and reflex DNA screening for trisomy 21, 18 and 13.
    Bestwick JP; Wald NJ
    PLoS One; 2019; 14(7):e0220053. PubMed ID: 31344071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis.
    Beulen L; Grutters JP; Faas BH; Feenstra I; van Vugt JM; Bekker MN
    Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():53-61. PubMed ID: 25238658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing value for money in medical screening.
    Cairns JA; Shackley P
    J Med Screen; 1994 Jan; 1(1):39-44. PubMed ID: 8790484
    [No Abstract]   [Full Text] [Related]  

  • 20. [Down syndrome--is it a disease or not?].
    Nau JY
    Rev Med Suisse; 2011 Jun; 7(300):1382-3. PubMed ID: 21815542
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.